๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Metastatic Castration-resistant Prostate Cancer
Clinical trial register · United States · industry-sponsored

Metastatic Castration-resistant Prostate Cancer Trials in the USA

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors โ€” the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice โ€” all 9094 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
9094
Studies in scope
industry-sponsored, all four open statuses
4935
Recruiting now
open to new participants
2188
Lead sponsors
across recruiting studies
Top states
California 32 Florida 22 New York 13 Illinois 12 Texas 12
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to
38 of 9094 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06067841Metastatic Castration-resistant Prostate Cancer
Bristol-Myers Squibb
Phase 1
140
California, Florida, Massachusetts, New York, North Carolina, Texas, Washington
2023-10-18
Recruiting
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
NCT05519449Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer
Janux Therapeutics
Phase 1
272
Alabama, Arizona, California, Connecticut, Florida, Illinois, Maryland, Minnesota
2022-09-15
Recruiting
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer
AstraZeneca
Phase 2
454
California, Indiana, Kansas, Massachusetts, Michigan, New Jersey, New Mexico, New York
2022-09-06
Recruiting
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
NCT05413850Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms
Blue Earth Therapeutics Ltd
Phase 1/2
82
Florida, Georgia, Nebraska, New York
2022-07-20
Active, closed
Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
NCT05219500Metastatic Castration Resistant Prostate Cancer
Fusion Pharmaceuticals Inc.
Phase 2
115
Nebraska, Texas
2021-12-16
Recruiting
A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
NCT05125016Metastatic Castration-resistant Prostate Cancer
Regeneron Pharmaceuticals
Phase 1/2
228
California, Connecticut, Kentucky, Maryland, New Jersey, New York, North Carolina, Ohio
2021-11-30
Recruiting
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
NCT04986423Metastatic Castration-Resistant Prostate Cancer
Zenith Epigenetics
Phase 2
200
California, Colorado, Florida, Louisiana, Maryland, Michigan, New York, North Carolina
2021-09-08
Recruiting
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
NCT04729114Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
Astellas Pharma Global Development, Inc.
Phase 1
174
Arizona, California, Florida, Indiana, Kansas, Maryland, Nebraska, New Jersey
2021-06-14
Active, closed
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
NCT04647526Metastatic Castration-Resistant Prostate Cancer
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Phase 3
455
Arizona, California, Colorado, Florida, Iowa, Kentucky, Louisiana, Maryland
2021-02-25
Active, closed
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
NCT03845166Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
Exelixis
Phase 1
325
California, Florida, Georgia, Iowa, Kansas, Maine, Maryland, Massachusetts
2019-03-20
Active, closed
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
NCT03732820Metastatic Castration-resistant Prostate Cancer
AstraZeneca
Phase 3
895
Alabama, Alaska, Arizona, California, Colorado, Illinois, Indiana, Louisiana
2018-10-31
Active, closed
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT02123758Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 1
57
California, Texas
2014-07-09
Rows per page Showing 26–38 of 38
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 18 September 2026. https://priyalifescience.com/clinical-trials-usa/condition/metastatic-castration-resistant-prostate-cancer

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.